1. Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380.

    Oncotarget 6(1):345 (2015) PMID 25514600

    The small molecule anticancer agent NSC-743380 modulates functions of multiple cancer-related pathways and is highly active in a subset of cancer cell lines in the NCI-60 cell line panel. It also has promising in vivo anticancer activity. However, the mechanisms underlying NSC-743380's selective...
  2. BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis

    Molecular Oncology 8(8):1429 (2014)

    Tumor cells have unstable genomes relative to non-tumor cells. Decreased DNA integrity resulting from tumor cell instability is important in generating favorable therapeutic indices, and intact DNA repair mediates resistance to therapy. Targeting DNA repair to promote the action of ant...
  3. BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis.

    Molecular Oncology 8(8):1429 (2014) PMID 24974076

    Tumor cells have unstable genomes relative to non-tumor cells. Decreased DNA integrity resulting from tumor cell instability is important in generating favorable therapeutic indices, and intact DNA repair mediates resistance to therapy. Targeting DNA repair to promote the action of anti-cancer a...
  4. BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis.

    Molecular Oncology 8(8):1429 (2014) PMID 24974076

    Tumor cells have unstable genomes relative to non-tumor cells. Decreased DNA integrity resulting from tumor cell instability is important in generating favorable therapeutic indices, and intact DNA repair mediates resistance to therapy. Targeting DNA repair to promote the action of anti-cancer a...
  5. BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis.

    Molecular Oncology 8(8):1429 (2014) PMID 24974076

    Tumor cells have unstable genomes relative to non-tumor cells. Decreased DNA integrity resulting from tumor cell instability is important in generating favorable therapeutic indices, and intact DNA repair mediates resistance to therapy. Targeting DNA repair to promote the action of anti-cancer a...
  6. Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer.

    Oncologist 19(9):909 (2014) PMID 25117064 PMCID PMC4153464

    A biomarker that predicts bone metastasis based on a protein laboratory assay has not been demonstrated. Reverse-phase protein array (RPPA) enables quantification of total and phosphorylated proteins, providing information about their functional status. The aim of this study was to identify bone...
  7. Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer.

    Oncologist 19(9):909 (2014) PMID 25117064 PMCID PMC4153464

    A biomarker that predicts bone metastasis based on a protein laboratory assay has not been demonstrated. Reverse-phase protein array (RPPA) enables quantification of total and phosphorylated proteins, providing information about their functional status. The aim of this study was to identify bone...
  8. Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer.

    Oncologist 19(9):909 (2014) PMID 25117064 PMCID PMC4153464

    A biomarker that predicts bone metastasis based on a protein laboratory assay has not been demonstrated. Reverse-phase protein array (RPPA) enables quantification of total and phosphorylated proteins, providing information about their functional status. The aim of this study was to identify bone...
  9. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.

    Cancer Biology & Therapy 15(7):919 (2014) PMID 24755674 PMCID PMC4100993

    This investigation describes the clinical significance of phosphorylated focal adhesion kinase (FAK) at the major activating tyrosine site (Y397) in epithelial ovarian cancer (EOC) cells and tumor-associated endothelial cells. FAK gene amplification as a mechanism for FAK overexpression and the ...
  10. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.

    Cancer Biology & Therapy 15(7):919 (2014) PMID 24755674 PMCID PMC4100993

    This investigation describes the clinical significance of phosphorylated focal adhesion kinase (FAK) at the major activating tyrosine site (Y397) in epithelial ovarian cancer (EOC) cells and tumor-associated endothelial cells. FAK gene amplification as a mechanism for FAK overexpression and the ...
  11. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.

    Cancer Biology & Therapy 15(7):919 (2014) PMID 24755674 PMCID PMC4100993

    This investigation describes the clinical significance of phosphorylated focal adhesion kinase (FAK) at the major activating tyrosine site (Y397) in epithelial ovarian cancer (EOC) cells and tumor-associated endothelial cells. FAK gene amplification as a mechanism for FAK overexpression and the ...
  12. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.

    Cancer Biology & Therapy 15(7):919 (2014) PMID 24755674 PMCID PMC4100993

    This investigation describes the clinical significance of phosphorylated focal adhesion kinase (FAK) at the major activating tyrosine site (Y397) in epithelial ovarian cancer (EOC) cells and tumor-associated endothelial cells. FAK gene amplification as a mechanism for FAK overexpression and the ...
  13. Notch3 pathway alterations in ovarian cancer.

    Cancer Research 74(12):3282 (2014) PMID 24743243 PMCID PMC4058356

    The Notch pathway plays an important role in the growth of high-grade serous ovarian (HGS-OvCa) and other cancers, but its clinical and biologic mechanisms are not well understood. Here, we found that the Notch pathway alterations are prevalent and significantly related to poor clinical outcome ...
  14. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer.

    Clinical Cancer Research 20(12):3280 (2014) PMID 24756370 PMCID PMC4062703

    Residual disease following primary cytoreduction is associated with adverse overall survival in patients with epithelial ovarian cancer. Accurate identification of patients at high risk of residual disease has been elusive, lacking external validity and prompting many to undergo unnecessary surg...
  15. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.

    Clinical Cancer Research 20(8):2226 (2014) PMID 24583795 PMCID PMC3989412

    Recent studies suggested that AKT activation might confer poor prognosis in acute myelogenous leukemia (AML), providing the rationale for therapeutic targeting of this signaling pathway. We, therefore, explored the preclinical and clinical anti-AML activity of an oral AKT inhibitor, MK-2206. Exp...
  16. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.

    Clinical Cancer Research 20(8):2226 (2014) PMID 24583795 PMCID PMC3989412

    Recent studies suggested that AKT activation might confer poor prognosis in acute myelogenous leukemia (AML), providing the rationale for therapeutic targeting of this signaling pathway. We, therefore, explored the preclinical and clinical anti-AML activity of an oral AKT inhibitor, MK-2206. Exp...
  17. Most expression and splicing changes in myotonic dystrophy type 1 and type 2 skeletal muscle are shared with other muscular dystrophies

    Neuromuscular Disorders 24(3):227 (2014)

    The prevailing pathomechanistic paradigm for myotonic dystrophy (DM) is that aberrant expression of embryonic/fetal mRNA/protein isoforms accounts for most aspects of the pleiotropic phenotype. To identify aberrant isoforms in skeletal muscle of DM1 and DM2 patients, we performed exon-...
  18. Most expression and splicing changes in myotonic dystrophy type 1 and type 2 skeletal muscle are shared with other muscular dystrophies.

    Neuromuscular Disorders 24(3):227 (2014) PMID 24332166 PMCID PMC3943873

    The prevailing pathomechanistic paradigm for myotonic dystrophy (DM) is that aberrant expression of embryonic/fetal mRNA/protein isoforms accounts for most aspects of the pleiotropic phenotype. To identify aberrant isoforms in skeletal muscle of DM1 and DM2 patients, we performed exon-array prof...
  19. Most expression and splicing changes in myotonic dystrophy type 1 and type 2 skeletal muscle are shared with other muscular dystrophies.

    Neuromuscular Disorders 24(3):227 (2014) PMID 24332166 PMCID PMC3943873

    The prevailing pathomechanistic paradigm for myotonic dystrophy (DM) is that aberrant expression of embryonic/fetal mRNA/protein isoforms accounts for most aspects of the pleiotropic phenotype. To identify aberrant isoforms in skeletal muscle of DM1 and DM2 patients, we performed exon-array prof...
  20. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.

    Nature Communications 5:3459 (2014) PMID 24619206 PMCID PMC4112501

    Improving small interfering RNA (siRNA) efficacy in target cell populations remains a challenge to its clinical implementation. Here, we report a chemical modification, consisting of phosphorodithioate (PS2) and 2'-O-Methyl (2'-OMe) MePS2 on one nucleotide that significantly enhances potency and...